2024-07-29T15:49:52-05:00 2023-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2023-01-01 263727917 Reagan-Udall Foundation for the Food and Drug Administration Inc REAG 2028492075 1333 New Hampshire Ave NW 420 Washington DC 20036 Susan C Winckler RPh Esq Chief Executive Officer 2028492075 2024-07-29 1 1 Jie Chen CPA P01049760 7038930300 2023 2024-08-08 14:25:15Z Susan C Winckler RPh E 1333 New Hampshire Ave NW 420 Washington DC 20036 9060787 0 X www.reaganudall.org X 2009 MD Advance the mission of the Food and Drug Administration to modernize product development, accelerate innovation, and enhance product safety. 17 17 19 24 0 0 5204924 4698615 3614197 3399686 30611 145939 -97503 -27513 8752229 8216727 0 10000 0 0 2344902 2651989 0 0 188321 6288520 5128287 8633422 7790276 118807 426451 8144687 6385158 4398051 2209540 3746636 4175618 Advance the mission of the Food and Drug Administration to modernize product development, accelerate innovation, and enhance product safety. 0 0 4936958 10000 3311805 Encourage innovative research & analysis - Provide data assets and analysis tools to examine the risks and benefits of regulated products. Examples include the COVID-19 Evidence Accelerator, the Innovation in Medical Evidence and Development Surveillance (IMEDS) Program, and the Algorithm Validation Studies Program.Education - The newly created Fellowship inRegulatory Science, Innovation, and Health Equityprovides a hands-on learning opportunity for professional school graduates. 1484690 51131 Improve public understanding of the risks and benefits of FDA-regulated products - Identify priority areas for consumer, patient, and provider education in areas of emerging science. Examples include the Skin Lightening Consumer Safety Project, Expanded Access Navigator, COVID-19 Hub, Antimicrobial Use Data in Food Animals, and the Nutrition Communication Network. 926606 36750 Facilitate multi-stakeholder collaboration - Enable expert analysis and candid discussion on issues relevant to the FDA mission. Examples include Patient Listening Sessions, Substance Use Disorders, and multiple expert convenings. 7348254 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 36 0 1 19 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X Dave Woodbury 2028492067 1333 New Hampshire Ave NW 420 Washington DC 20036 Richard Schilsky Chair 4.00 X X 0 0 0 Georges Benjamin Vice Chair 4.00 X X 0 0 0 Allan Coukell Secretary/Treasurer 4.00 X X 0 0 0 Ed Allera Director 4.00 X 0 0 0 Phil Febbo Director 4.00 X 0 0 0 Adrian Hernandez Director 4.00 X 0 0 0 Esther Krofah Director 4.00 X 0 0 0 PK Morrow Director 4.00 X 0 0 0 Richard Moscicki Director 4.00 X 0 0 0 Debra Ness Director 4.00 X 0 0 0 Andrew von Eschenbach Director 4.00 X 0 0 0 Lynne Zydowsky Director 4.00 X 0 0 0 Christie Boutte Director 4.00 X 0 0 0 Molly Fogarty Director 4.00 X 0 0 0 James Hildreth Director 4.00 X 0 0 0 David Fajgenbaum Director 4.00 X 0 0 0 William Hait Director 4.00 X 0 0 0 Susan C Winckler RPh JD Chief Executive Officer 40.00 X 405516 0 35586 Amar Bhat PhD Chief Operating Officer 40.00 X 214440 0 30271 Carla Rodriguez-Watson PhD Director, Research 40.00 X 208577 0 23670 Lea Ann Browning-McNee MA Director, Communication & Stakeholder Engagement 40.00 X 175872 0 28828 David E Woodbury Jr MBA Director, Operations 40.00 X 165719 0 29537 Carolyn Hiller MBA Senior Advisor for Innovation & Strategic Partners 40.00 X 155375 0 29520 Mary McNamara Communications Manager 40.00 X 105847 0 19041 1431346 0 196453 7 0 1 0 Evidence to Practice LLC 1329 Grand Canopy Drive Severn MD 21144 Professional consulting services 349964 Angela Hoth 905 Rider Street Iowa City IA 52246 Professional consulting services 153154 Alston & Bird LLP PO Box 933124 Atlanta GA 311933124 Legal services 140000 Beacon Hill Staffing Group PO Box 846193 Boston MA 02284 Temp staffing services 111115 Calibre CPA Group PLLC 7501 Wisconsin Avenue Suite 1200 W Bethesda MD 20814 Accounting services 102454 5 323950 4177302 197363 4698615 IMEDS Contract 541900 3399686 3399686 3399686 132034 132034 750000 736095 13905 13905 13905 29580 323950 107965 -78385 -78385 Other 900099 50872 50872 50872 8216727 3399686 0 118426 X 10000 10000 685813 620784 27160 37869 1594541 1443345 63147 88049 89600 81103 3549 4948 130733 118337 5177 7219 151302 136955 5992 8355 120988 120340 190 458 123914 123914 4185933 4155649 9919 20365 37289 37089 59 141 31400 28822 989 1589 165690 162023 1346 2321 251379 232242 8439 10698 4825 4719 34 72 103227 100952 737 1538 41113 37736 1297 2080 11172 10255 352 565 Professional developmen 25385 22978 1005 1402 Dues and subscriptions 11790 10822 372 596 IRB expense 9401 9350 15 36 Scientific publishing 4740 4715 7 18 41 38 1 2 7790276 7348254 253701 188321 490499 526766 2775826 3310505 750430 704030 1721442 148785 33861 46148 444218 326468 115791 117750 769732 250893 7500 5626 1479606 1274655 8144687 6385158 2856234 403452 311414 1541817 1494674 4398051 2209540 X 3689939 4121734 56697 53884 3746636 4175618 8144687 6385158 X 426451 7531 -5000 X X 0 1 X 1 1 1 X 1800144 2391995 2762920 5204924 4698615 16858598 1800144 2391995 2762920 5204924 4698615 16858598 16858598 35048 22326 1358 30611 132034 221377 1144 1090 50872 53106 17133081 13145965 0.98400 0.96560 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 26254 5626 20628 193225 118203 75022 224739 202639 22100 117750 Deposits 26308 Right-of-use assets - operating lease 1248347 1274655 Lease liability - operating lease 1494674 1494674 X 8332223 7531 107965 115496 8216727 0 8216727 7903241 112965 112965 7790276 0 7790276 Part X, Line 2: Management has evaluated the Foundation's tax positions and concluded that the Foundation's financial statements do not include any uncertain tax positions. Part XI, Line 2d - Other Adjustments: Direct benefits to donors 107,965. Part XII, Line 2d - Other Adjustments: Direct benefits to donors 107,965. Write-off of contribution 5,000. 2023 Awards Gala 353530 323950 29580 52515 55450 353530 323950 29580 52515 55450 107965 -78385 1 Friends of Cancer Research 1800 M Street NW Suite 1050 South Washington DC 20036 521983273 501(c)(3) 10000 0 2023 Annual Cancer Leadership Awards sponsorship 1 Part I, Line 2: RUF reviews grant reports and monitors grant progress toward milestones. X 0 0 0 0 0 0 0 0 0 Susan C Winckler RPh JD Chief Executive Officer 405516 0 0 0 0 0 19800 0 15786 0 441102 0 0 0 Amar Bhat PhD Chief Operating Officer 211940 0 2500 0 0 0 13035 0 17236 0 244711 0 0 0 Carla Rodriguez-Watson PhD Director, Research 206077 0 2500 0 0 0 12960 0 10710 0 232247 0 0 0 Lea Ann Browning-McNee MA Director, Communication & Stakeholde 173372 0 2500 0 0 0 11087 0 17741 0 204700 0 0 0 David E Woodbury Jr MBA Director, Operations 163719 0 2000 0 0 0 10200 0 19337 0 195256 0 0 0 Carolyn Hiller MBA Senior Advisor for Innovation & Stra 152875 0 2500 0 0 0 9465 0 20055 0 184895 0 0 0 Form 990, Part VI, Section B, line 11b After the Form 990 is prepared by the independent accountants it is reviewed by the Chief Executive Officer and the Treasurer before being filed with the IRS. Form 990, Part VI, Section B, line 12c No director, officer, employee, fellow or trainee of the Foundation (hereinafter "Interested Persons") shall take any action on or participate in the consideration or determination of any Foundation matter in which he or she, his or her spouse, minor child, general partner, non-federal organization in which he or she is serving as an officer, director, trustee, general partner or employee, or any person or nonfederal organization with whom he or she is negotiating or has any arrangement concerning potential employment, has a financial interest. In addition to actual conflicts of interest, Interested Persons are also obliged to avoid actions that could be perceived or interpreted to be in conflict with the Foundation's best interests. Interested Persons shall disclose their financial interest in entities doing business with the Foundation and refrain from participating in decisions affecting transactions between the Foundation and those other entities without approval by the Board of Directors. Form 990, Part VI, Section B, line 15a The CEO's performance and compensation is annually reviewed and approved by the Executive Committee with input from the Board. This entire process is documented. Salaries of all staff are reviewed annually by the CEO using compensation survey data for comparable size and type organizations. Form 990, Part VI, Section C, line 19 The Foundation makes its governing documents, conflict of interest policy, and financial statements available to the public upon request. Form 990, Part IX, line 11g Temporary staff expense: Program service expenses 78,855. Management and general expenses 3,450. Fundraising expenses 4,810. Total expenses 87,115. Data partners: Program service expenses 2,643,613. Management and general expenses 4,184. Fundraising expenses 10,063. Total expenses 2,657,860. Staff recruiting expense: Program service expenses 27,676. Management and general expenses 44. Fundraising expenses 104. Total expenses 27,824. Payroll service fees: Program service expenses 4,457. Management and general expenses 8. Fundraising expenses 17. Total expenses 4,482. Other professional fees: Program service expenses 52,776. Management and general expenses 99. Fundraising expenses 239. Total expenses 53,114. Program consultants: Program service expenses 1,348,272. Management and general expenses 2,134. Fundraising expenses 5,132. Total expenses 1,355,538. Form 990, Part XI, line 9: Write-off of contribution -5,000. Form 990, Part XII, Line 2c: The Foundation's Finance Committee is responsible for oversight of the audit, including selection of the independent accountant. The process has not changed from prior years.